Newsletter | November 19, 2026

11.19.26 -- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 2

FOCUS ON MANUFACTURING

Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 2

In Part 2 of 2, Dr. Haydar Frangoul discusses long-term safety and durability of gene editing in children with SCD and TDT, plus the infrastructure, specialized expertise, and referral pathways needed to expand access to treatment.

How Cell Therapy's Fundamentally Different Model Impacts Patients

Examine the evolution of autologous CAR T therapies, their patient-specific manufacturing workflow, key similarities and differences with biologics production, and real-world approaches.

Execution Intelligence: Embedding AI Inside Validated Manufacturing

In regulated manufacturing, AI creates value when embedded in validated execution rather than layered above it, tied to batch state, workflow governance, and QA authority.

Enabling MSC Harvest, Wash, And Concentration

A study demonstrates how a low-shear, closed-system centrifuge achieved over 90% MSC recovery and minimized viability loss, supporting scalable cell therapy manufacturing.

Decoding AAV: Navigating Critical Quality Attributes And Their Analytics

For groundbreaking genetic treatments, stringent quality control is non-negotiable. This exploration delves into defining essential attributes and the analytical tools that safeguard their consistent production.

Designing For Control: Minimizing Particulate Risk In Aseptic Sites

Effective particulate control in aseptic fill/finish operations requires coordinated design decisions spanning airflow configuration, static mitigation, transport mechanisms, and closure handling.

Release, Redefined: QC Testing Across In Vivo And Ex Vivo CAR-T

As CAR-T manufacturing evolves, QC strategies must adapt. Learn how identity, potency, sterility, and safety testing support faster release decisions and broader patient access.

Scaling iPSC Aggregate Culture With Bioreactors

Controlled aggregation, oxygen management, and scalable workflows drive consistent expansion. Parallelized systems improve reproducibility for optimization.

Cutting Biomanufacturing Costs Through Process Intensification

Explore two projects that a focus on improving efficiency and productivity in biopharmaceutical manufacturing while reducing the cost of goods through process intensification.

Advancing Residual E. coli DNA Testing For Biologics And CGTs

Advancements in high-sensitivity residual DNA testing enhance the precision of plasmid DNA purity analysis, ensuring compliance with regulatory standards critical for manufacturing processes.

Contamination Control Strategies In Low Bioburden Manufacturing

Annex 1’s updated CCS framework calls for a holistic contamination strategy. Learn how manufacturers can apply it to non-sterile sites and legacy facilities using tailored risk-based approaches.

Precision At Scale: Optimizing Cell-Free DNA Manufacturing For mRNA Vaccines

Backbone-free enzymatic DNA templates can improve polyA integrity, long-transcript quality, and RNA yield, with implications for IVT timelines and regulation.

Selecting The Right Methods For Sterile Water Manufacturing And QC Testing

Understanding which USP water monographs require bacterial endotoxin testing, sterility testing, or both helps laboratories select the right methods and avoid compliance gaps.

MANUFACTURING SOLUTIONS

•

A Scaled-Down Solution For Simple, Robust Upstream Intensification - Repligen

•

GMP Cell Bank Manufacturing Technology - RoosterBio

•

Increased Productivity At Commercial Scale - Cytiva

•

Elutriation And Washing In One System - Invetech

•

Protein Chromatography Sample And Buffer Filtration Starter Kit - Cytiva

•

40μm And 150μm Filters For Bioprocessing Applications - Charter Medical

Connect With Cell & Gene: